Cytox Company
Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer's Disease in the very early stages. Alzheimer's Disease affects over 26 million people world-wide and is a growing condition as people live longer. There is currently no cure for Alzheimer's Disease, but there are large international initiatives underway to find treatments with many drugs in clinical development. Cytox are commercially launching their tests in conjunction with Affymetrix (part of Thermo Fisher Scientific) to support Pharmaceutical and Biotechnology companies developing novel therapeutics.
Investors
.png)
.jpeg)
(Reupload).png)
.png)
.jpg)
(Reupload).png)
Technology:
Biotechnology, Genetics
Industry:
Clinical Development
Headquarters:
Manchester, Manchester, United Kingdom
Founded Date:
2004-01-01
Employees Number:
1-10
Funding Status:
Early Stage Venture
Investors Number:
15
Total Funding:
15484781
Estimated Revenue:
$1M to $10M
Last Funding Date:
2019-01-01
Last Funding Type:
Grant
Register and Claim Ownership